Budget 2026 could stem FII’s selling pressure, says Sudip Bandyopadhyay

As foreign portfolio investors (FPIs) continue to exit Indian markets amid global uncertainties, Budget 2026 could play a crucial role in stabilizing stock sentiment, says market expert Sudip Bandyopadhyay. Strategic measures targeting FII issues should be the main focus for policymakers, he emphasized.“The only surprise announcement I am looking forward to is if they go […]

FII return seen as key trigger for Nifty’s next breakout: Sudip Bandyopadhyay

Indian shares may have regained the 26,000-point mark on the Nifty, but maintaining this level will depend heavily on global signals – especially a possible US-India trade deal – according to market expert Sudip Bandyopadhyay. Speaking to ET Now, he said the recent upturn is encouraging but far from a decisive breakthrough.“In the near future, […]

Defense stocks falling? Buy the fix, stay 5 years; go for niche tech over big IT: Sudip Bandyopadhyay

India’s defense rally may bring bouts of volatility, but investors should view any dip as an entry point – only if they are willing to stay invested for at least three to five years, says Sudip Bandyopadhyay, group chairman of Inditrade Capital. Speaking to ET Now, he highlighted that defense remains one of India’s strongest […]

US market rally driven more by sentiment than substance: Sudip Bandyopadhyay

While global markets are recovering on renewed optimism about potential trade progress between the US and China, questions remain about how sustainable this upward trend really is. The rise in US stock prices, largely driven by sentiment, comes ahead of the highly anticipated meeting between President Xi Jinping and President Donald Trump. In an exclusive […]

Pharma rates and value Retailers: Sudip Bandyopadhyay Downies Market Outlook

The pharmaceutical sector of India may not be in the headlines, but tariff -related uncertainties remain an important care for investors, says MarktExpert Sudip Bandyopadhyay. “Rate is the greatest uncertainty. Apart from Sun Pharma, most companies are not affected by the current American tariff regime. Even Sun will even avoid the bullet with recent developments. […]